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Abstract
Background: Clinical presentation, diagnosis, management and outcome of molecularly defined congenital
pulmonary alveolar proteinosis (PAP) due to mutations in the GM-CSF receptor are not well known.
Case presentation: A 2 1/2 years old girl was diagnosed as having alveolar proteinosis. Whole lung lavages were
performed with a new catheter balloon technique, feasible in small sized airways. Because of some interstitial
inflammation in the lung biopsy and to further improve the condition, empirical therapy with systemic steroids
and azathioprin, and inhaled and subcutaneous GMCSF, were used. Based on clinical measures, total protein and
lipid recovered by whole lung lavages, all these treatments were without benefit. Conversely, severe respiratory
viral infections and an invasive aspergillosis with aspergilloma formation occurred. Recently the novel homozygous
stop mutation p.Ser25X of the GMCSF receptor alpha chain was identified in the patient. This mutation leads to a
lack of functional GMCSF receptor and a reduced response to GMCSF stimulation of CD11b expression of
mononuclear cells of the patient. Subsequently a very intense treatment with monthly lavages was initiated,
resulting for the first time in complete resolution of partial respiratory insufficiency and a significant improvement
of the overall somato-psychosocial condition of the child.
Conclusions: The long term management from early childhood into young adolescence of severe alveolar
proteinosis due to GMCSF receptor deficiency requires a dedicated specialized team to perform technically
demanding whole lung lavages and cope with complications.
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Background
Pulmonary alveolar proteinosis (PAP) is characterized by
a substantial and persistent increase in surfactant pool
size [1,2]. There are several causes of this rare condition;
mouse models with deletion of granulocyte-macrophage-
colony stimulating factor (GM-CSF) or the GM-CSF
receptor (GM-CSFR) beta-chain showed the first evi-
dence for involved molecularly mechanisms [3,4]. Auto-
antibodies against GM-CSF, blocking GM-CSF signaling,
are the cause for the most frequent form of PAP, mainly
found in adults and also called autoimmune PAP [5]. In
2008 the first two families with congenital PAP and
mutations in the alpha-chain of the receptor for GM-CSF
were described [6,7] and very recently another six
families were reported [8]. The patients presented with
progressive dyspnea of insidious onset between the ages
of 1.5 and 9 years; some were asymptomatic. Short term
responsiveness to whole lung lavage (WLL) treatment
has been described, however not much information on
the long term outcome of molecularly defined patients is
yet available.
Other genetic conditions that lead to PAP include a
recently identified mutation in the beta chain of the
GMCSF receptor [9], surfactant protein B or C deficiency
[10,11], Niemann-Pick Type C2 disease [12] and lysinuric
protein intolerance [13]. Secondary PAP develops in
association with conditions involving functional impair-
ment or reduced numbers of alveolar macrophages like
inhalation of inorganic dusts, myeloic leukemia,
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myelodysplastic syndrome, immunosuppression related
to organ transplantation, and some infections including
Pneumocystis [1].
Not much is known on the clinical spectrum, course
and treatment options in patients with molecularly
defined, congenital PAP due to mutations in the GM-
CSF alpha chain. Also the role of long term WLL,
which are be very demanding due to the small size of
the airways, how to measure clinical response to lavage
therapy and the relevance of glucocorticoid therapy have
not been reported. Here we present the successful man-
agement of a child with a severe congenital PAP caused
by the homozygous p.Ser25X mutation in exon 3 of the
CSF2RA gene and its follow up for more than a decade.
These data may be helpful for future treatment of
infants and children with this rare condition.
Case Presentation
The patient was the 2nd of 3 living children; born at term
in 1998, with no immediate postnatal respiratory distress.
The family history was unremarkable for pulmonary or
other rare diseases; the parents were consanguineous and
of Turkish descent. At age 2 1/2 years during an acute
respiratory tract infection with productive cough and
fever with no response to antibiotics, intermittent cyano-
sis occurred and the child was referred to our centre
because of chronic tachypnoea and weight loss. Because
of a typical chest computed tomography (CT) and chest
x-ray (Figure 1A, B), BAL macroscopic appearance
(Figure 1G) and microscopy (Figure 1C, H), and after
exclusion of infectious or metabolic causes or malig-
nancy, PAP was suspected and confirmed by histology
(Figure 1F, I).
Figure 1 Diagnosis of alveolar proteinosis was suspected based on typical radiological picture in chest x-ray and CT with ground-
glass attenuation and interstitial thickening, resulting in crazy paving pattern (Figure. 1 A, B). Figure. 1 E shows CT after whole lung
lavage of the right lung. Macroscopic appearance (Figure. 1 G) and light microscopy of BAL fluid stained with PAS (Figure. 1 C, magnification
x400) showed extracellular positive proteinaceous material, lipid-laden macrophages (Figure. 1 H, MGG stain, magnification x1000), and after
exclusion of infectious or metabolic causes or malignancy, PAP was confirmed by histology (right lower lobe). HE stained tissue demonstrated
alveolar filling with eosinophilic material (Figure. 1 F) which was positive in periodic acid stain (PAS)(Figure. 1 I), intraalveolar cholesterol clefts
(Figure. 1 H, arrows) and characteristic oval bodies (Figure. 1 H, open arrow).
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At presentation the child had global respiratory insuffi-
ciency, combined with an elevated level of LDH and CEA
(Figure 2A). Based on the clinical diagnosis of alveolar
proteinosis we initiated whole lung lavages and some
additional treatments.
Therapeutic bronchoalveolar lavages of either the right
or left lung were performed under general anaesthesia
and paralysis. From age 2 1/2 to 6 years we used a techni-
que that isolated one lung with the help of a balloon
catheter (5-7 Fr, Arrow, Reading, USA) placed into one
Figure 2 Long term clinical course and treatments. Lactate dehydrogenase (LDH), height, weight for height (WfH) expressed as the current
weight of the child as a percentage of the normal weight for a given height, capillary CO2 pressure, and carcino embryonic antigen, CEA in
serum (Figure. 2 A). For nutrition a percutaneous gastrostomy (PEG) and later a jejunostoma were implemented. Whole lung lavages (WLL) were
performed as indicated; at age 5 years four consecutive lavages were done with perfluorocarbon (PFC BAL). Further abbreviations: ARDS: acute
respiratory distress syndrome, LLL: left lower lobe, NIV: non invasive nasal-mask ventilation, PIV: Parainfluenza virus (Figure. 2 B).
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main stem bronchus through the cuffed endotracheal
tube (ID 4.0-5.0) and blocked there (see also Figure 3A).
The position and fitting of the catheter was permanently
monitored via an Olympus bronchoscope (BFN20, O.D.
1.8 mm), as described in detail [14]. From age 7 onward
the size of the main bronchus was sufficient to allow
double lumen tube and lavage of one lung, while ventilat-
ing the other. Sterile 0.9% NaCl warmed to body tem-
perature was used as lavage fluid. The lavage was done
by manual injection and withdrawal of saline from a
50 ml syringe, starting with smaller volumes of 4 ml/kg
body weight (used for diagnostic purposes) and increas-
ing to about 11 to 15 ml/kg under continuous control of
the correct position and tightness of the balloon. The
recovered fluid was collected via a 2-way cock stop into
500 ml bottles to allow judgement of turbidity and to
follow the process of lavage [15]. In 2003, at age 5 y, we
tried to increase the yield of lipo-proteins recovered from
the lungs with the help of perfluorocarbons (PFC)
[16,17]. A total of 100 ml of Perfourodecalin (Pharmpur,
Augsburg, Germany) was instilled in 3 aliquots after the
6th, 7th, or 8th 500 ml wash during three consecutive
WLL sessions. This approach did neither improve the
yield of phospholipids washed out (Figure 4A, B) nor that
of total protein (not shown).
Empirically, we found that WLL were the most efficient
treatment. This was clearly shown for the short term;
during 49 instances investigated until the age of 11, the
amount of nasal oxygen flow was reduced in 40 after the
lavages (Figure 3B). This effect could be sustained for
many years demonstrating long term efficacy. However
the extreme value of WLL was only very recently
Figure 3 Whole lung lavages were performed, due to the small sizes of the airways until the age of 6 y, via a blocked endotracheal
tube through which the child was ventilated (Figure. 3 A, 1.) and through which also a pulmonary artery catheter (Figure. 3 A, 3.,
blue) was inserted and blocked in the left or right main stem bronchus (small syringe) and the lavage was done (Figure. 3 A, 4., large
syringe). The tight fit of the blocked pulmonary artery catheter was continuously monitored via a 1.8 mm endoscope (Figure. 3 A, 2., black).
Figure. 3 B shows the change of nasal flow of oxygen before and after the first 49 whole lung lavages (P < 0.0001, paired comparison by
Wilcoxon test); in the figure values are ordered according observed change in oxygen flow ("triangle tip down” indicates reduced flow after
lavage, “triangle tip upwards” indicates increased flow of oxygen after lavage, and “ = “ indicates unchanged flow of oxygen. From year 10
onward lung function tests were performed, forced vital capacity (FVC) improved dramatically with more intensely performed lavages (not
shown), as did forced expiratory volume in 1 second (FEV1) (Figure. 3 C).
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demonstrated unequivocally following implementation of
our concept of very aggressive WLL. Up to the age of 10
years, WLL were done more or less to ameliorate partial
respiratory insufficiency, i.e. to decrease the need for
additional oxygen. From year 10 onward, we performed
one lavage per month, in order to try to completely clear
the lung from its proteinosis load. This approach was
very successful and resulted in complete resolution of
partial respiratory insufficiency for the first time. The
patient started puberty, growth and weight were sustained
by oral nutrition without need of using the percutaneous
tube and the dependency on supplemental oxygen up to
that point in time, could be finished. This also led to
increased self-confidence and better integration at school.
Also, the lung function improved very rapidly and chest
radiograph cleared to almost normal (Figure 1D, E; Figure
3C). Together somato-psychosocial condition substan-
tially improved. A consecutive brief trial to increase the
time lag between the lavages failed and an interval of
about 4 weeks was maintained.
Because at clinical diagnosis of the patient, both the
exact cause of the PAP and effective treatments in small
children were unknown, empirical high dose glucocorti-
costeroids in pulses were used (Figure 2A) and under the
impression that they might be helpful, systemic corticos-
teroids were used for prolonged periods until the age of
7.5 years. During this time, azathioprine as a steroid saving
agent was also used without any apparent benefit. How-
ever, we clearly observed that severe infectious complica-
tions were only observed during the time of increased
immunosuppression by these agents (Figure 2A, B). At
5 years of age an Aspergillus fumigatus infection with
formation of a cavity, leading to severe cardio-respiratory
failure and resuscitation followed by resection of the left
lower lobe (Figure 2B, Figure 5A-D). At age 7.5 years
she suffered a pulmonary para-influenza infection, leading
to ARDS and necessitating mechanical ventilation. Addi-
tionally, the child had many mild respiratory exacerba-
tions, mostly believed to be induced by viral upper- and
lower respiratory tract infections.
Figure 4 At age 5 y, during four consecutive whole lung lavage sessions perfluorocarbon (PFC) was instilled into the lungs after the 6th, 7th,
or 8th of the 500 ml wash in order to enhance the recovery of surfactant material. The concentration of phosphoplipids (and total protein (not
shown)) washed out was not significantly altered compared to lavages done at that age without PFC (Figure. 4 A, B). From age 3 to 4 1/2 years therapy
with inhaled and subcutaneous injections of recombinant GM-CSF was done (see also Figure. 2 B). Although the intervals between consecutive
therapeutic whole lung lavages were increased with GM-CSF treatment the amount of protein removed was also increased, demonstrating no
reduction of protein amount with GM-CSF treatment (Figure. 4 C, D). Note that not all lavages were available for total protein measurements.
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Of interest, from age 3 to 4 1/2 years, well before the
molecular nature of the PAP was determined, we used
inhaled and subcutaneous recombinant GM-CSF (Figure
2B). A transient increase in peripheral blood eosinophils
up to 17% of the neutrophils occurred [18] (data not
shown), but clearly no improvement of the alveolar protei-
nosis (Figure 2A, B, Figure 4C, D). Due to the expectations
of the treating physicians, the intervals between consecu-
tive therapeutic WLL were increased during GM-CSF
treatment: In parallel, this was associated with an increased
load of protein, demonstrating a lack of an effect of GM-
CSF treatment (Figure 4C, D).
Nutritional support was optimized with the help of a
percutaneous gastrostomy (PEG, Figure 2B) placed at
the age of 3 years, which was used regularly; the gastro-
stomy was changed to a jejunostoma at the age of 61/2
years, to completely exclude gastro-esophageal refluxes,
although no such events had been demonstrated in pH-
or impedance studies (Figure 2B).
GM-CSF, the GM-CSF receptors and their functional
analysis
At age 12 years (in 2009) analysis of the patient’s CSF2RA
gene revealed the homozygous Ser25X stop-mutation in
exon 3 resulting in the almost complete absence of the
GM-CSF receptor alpha chain and causing the alveolar
proteinosis we observed (Figure 6A). The parents were
heterozygous for the mutation (Figure 6A, B). Mutations
in SFTPC, SFTPB and ABCA3 were excluded.
GM-CSF level were increased in serum (106 pg/ml,
normal < 6 pg/ml) of the child and normal in the parents.
No anti-GM-CSF autoantibodies were detected in serum
[19]. GM-CSF-Ra chain expression after stimulation with
50 ng/ml GM-CSF on peripheral mononuclear cells of
the patient was markedly reduced and normal in both
parents (Figure 6C). In the absence of GM-CSF stimula-
tion, GM-CSF-Ra chain in the parents was only 50% of
that of the controls (Figure 7A), whereas GM-CSF-Rb
chain and CD11b were normal. After stimulation with
Figure 5 Clinical complication. At age 5 years a chest CT (Figure. 5 A) showed a cavity and infiltration in the left lower lobe which was due to
an infection with Aspergillus fumigatus; the resected specimen showed an aspergilloma (black arrows) in the neighborhood of typical alveolar
proteinosis with surfactant filled alveoli (white arrows)(Figure. 5 D). Inside the cavity a neutrophilic infiltrate (Figure. 5 B) and infection with
aspergillus (Figure. 5 C, almost all fungi, arrows indicate neutrophils) was present.
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GM-CSF, GM-CSF-Ra and CD11b remained low in the
patient (Figure 7A, lower panel), whereas the parents’
levels were in the normal range level. GM-CSF-Rb chain
without and with GM-CSF stimulation was normal
(Figure 7A). CD11b expression on the neutrophils was
used to assess signal transduction after GM-CSF stimula-
tion. In the patient, similar as blocked by auto-antibodies
from a subject with auto-immune PAP, no dose-depen-
dent stimulation of CD11b was observed, demonstrating
interruption of signalling (Figure 7B).
Conclusions
Here we report a patient with molecularly defined severe
congenital PAP due to a previously undescribed autosomal
recessive mutation in the alpha chain of the GM-CSF
receptor. This mutation leads to a stop of transcription
and to a lack of functional protein. The GM-CSF induced
responses are mediated through activation of the tran-
scription factor PU.1 and include increased surfactant cat-
abolism and CD11b expression [20]. Impairment of the
latter was shown directly in mononuclear cells of the
patient after stimulation with GM-CSF. Impaired GMCSF
receptor activation of alveolar macrophages leads to
decreased surfactant catabolism and accumulation of sur-
factant in the alveolar space, i.e. alveolar proteinosis.
Important messages from this study are related to the
long-term management of this condition. First, persistent
and aggressive removal of surfactant filling the alveolar
space may eliminate gas exchange abnormalities and con-
secutive sequelae including developmental and growth
failure, and restricted level of performance due to
respiratory limitation. Second, immune insufficiency, a
Figure 6 Molecular diagnosis and mechanism. Sequence analysis of CSF2RA exon 3 in a control subject (Figure. 6 A, upper panel), in one of
the parents (Figure. 6 A, middle panel), and in the proband (Figure. 6 A, lower panel). In peripheral blood leukocytes genomic DNA, exons 3-13
of the CSF2RA gene were amplified and the PCR products were sequenced. The electropherograms illustrate the c.74 C > A substitution (boxed)
in heterozygous (middle panel) and in homozygous form (lower panel), which leads to the replacement of a serine (TCG) by a premature stop
codon (TAG) at amino acid position 25. Family tree shows consanguinity (Figure. 6 B). Flow cytometric analysis of peripheral blood cells
demonstrates the absence of the alpha-chain (Figure. 6 C). Isolated neutrophils were incubated with antibodies, washed with Dulbecco’s PBS
twice and measured by means of flow cytometry. Ten thousand cells were counted and analyzed by the FACSDiva software. Fc blocking and
isotype controls were applied to exclude unspecific bindings. CD11b (mouse monoclonal IgG1, PE conjugated), CD116/GM-CSF-R alpha (mouse
monoclonal IgG1, PE conjugated), CD131w/GM-CSF-R beta (mouse monoclonal IgG1, purified) and secondary antibody for CD131w (rat anti-
mouse IgG1, PE-conjugated).
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problem also primarily resulting from abnormalities of
the GM-CSF signal transduction pathway [20], may be
augmented by immunosuppressive therapy initiated to
treat the condition empirically. Therefore, molecular
genetic definition of the basic defect in all children with
PAP is important. Lastly, we describe the successful use
of outcome measures of the efficacy of therapeutic WLL,
including oxygen demand, and amount of washed out
protein and phospholipids.
A major strength of this study is to demonstrate the
feasibility of technically demanding repetitive WLL in a
very small child over extended periods of time. Although
therapeutic WLL is generally accepted as the established
treatment option for PAP in adults, its optimal method,
frequency of application and many other details are
currently not known in infants or children. Here we show
that consecutive lavages via a small catheter located in a
main stem bronchus (Figure 3A) can be used to efficiently
remove accumulated surfactant from the alveolar space in
a very small child. Furthermore we show that it is helpful
to monitor efficacy of the washing procedure by determi-
nation of proteins and lipids removed from the lungs [15].
These measurements allowed us to demonstrate only a
marginal, but not clinically significant increase in the
removal of surfactant material from the lungs, by the use
of PFC for lavage. In a case report on an infant with alveo-
lar proteinosis due Niemann Pick disease the usage of PFC
was recently shown not to be of benefit as well [21].
Although feasibility of the long term management of
congenital PAP with WLL was demonstrated in this
Figure 7 Molecular diagnosis and mechanism. Peripheral neutrophils were isolated by means of density-gradient centrifugation with Ficoll
(GE Healthcare, Munich, Germany and assessed in the presence and absence of GM-CSF for the expression of the GM-CSF Ra and Rb chain, and
CD11b. The purity of neutrophils was greater than 95% as assessed by differential cell counts of Pappenheim cytospin preparations. Cell viability
was greater than 95% using trypan-blue exclusion method. 106 neutrophils were treated with 50 ng/ml GM-CSF or the same volume of the
vehicle buffer (aqua a.i.) for 30 min at 37°C. In the absence of GM-CSF stimulation, GM-CSF-Ra chain expression in the parents was only 50% of
that of the controls (Figure. 3 A), whereas GM-CSF-Rb chain and CD11b expression were normal. After stimulation with GM-CSF, GM-CSF-Ra in
the patient remained low, whereas the parents’ level increased to almost control level. GM-CSF-Rb chain and CD11b stimulation were normal
(Figure. 3 A). CD11b expression on the neutrophils was used to assess signal transduction after GM-CSF stimulation. In the patient, similar as
blocked by auto-antibodies from a subject with auto-immune PAP, no dose-dependent stimulation of CD11b was observed, demonstrating
interruption of signalling (Figure. 3 B).
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case of severe PAP, molecular diagnosing PAP as caused
by a genetic deficiency of GM-CSFRa may have other
important prophylactic and therapeutic implications.
First, based on experiments in mice with PAP bone
marrow transplantation may cure the disease [3]. Cur-
rently we believe however that the risks of a bone mar-
row transplant (chronic graft versus host disease, among
others) outweigh its benefits (elimination of need for
WLL). Second, if diagnosed early in a family with an
index case, the opportunity of early intervention by
lavages at times of good clinical condition will help to
reduce complications.
Subcutaneous injections or inhalations of GM-CSF,
which have been successfully utilized in adult patients
with autoimmune PAP [22,23], were not helpful in our
case to reduce alveolar filling as assessed by CT scanning
(not shown) or improvement in gas exchange (Figure 2).
Treatment with 20 μg/kg of GM-CSF per day subcuta-
neously was also shown to be ineffective for the child
with congenital PAP described by Martinez-Moczygemba
et al. [7].
Immunosuppressive treatment was used empirically and
because of the presence of neutrophils and some lympho-
cytes in the lavage specimens and in the interstitial space
of the lung biopsy sample of the patient (Figure 2B).
Unfortunately severe and prolonged infections occurred,
including a cavity forming infection with Aspergillus fumi-
gatus which was treated by i.v. and inhaled amphotericin
B and surgical resection of the cavity. Sustained withdra-
wal of the systemic corticosteroids from age 8 years
onward did not alter the activity of the underlying PAP,
but reduced the rate of infectious respiratory complica-
tions considerably.
Our study exemplifies detailed long term management
of severe molecularly defined alveolar proteinosis from
childhood into young adolescence. It is of interest that a
dedicated specialized team may be advantageous to main-
tain the appropriate expertise of complex procedures such
as e.g. whole lung lavages in small children [8,15,24,25].
Therefore a centralized approach, as it has been employed
for rare lung diseases and PAP in particular on a national
basis in France [24], may be warranted. A web-based sys-
tem to collect these rare cases, follow them and also to
receive support is available at the kids lung register
(http://www.kids-lung-register.eu). The novel whole lung
lavages technique using an inflatable balloon catheter was
feasible in very small sized airways. Whereas empirical
immunosuppressive therapy and inhaled and subcuta-
neous GMCSF were without significant benefit, a very
intense treatment with WLL resulted in complete resolu-
tion of respiratory insufficiency, and a normalisation of
lung physiology and overall somato-psychosocial condition
of the child.
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